智通财经APP获悉，康宁杰瑞制药-B(09966)午后涨近7%，截至发稿，涨5.45%，报4.64港元，成交额3707.69万港元。
消息面上，康宁杰瑞制药较早前宣布，HER2双特异性抗体偶联药物JSKN003获国家药品监督管理局药品审评中心同意开展一项Ⅲ期临床研究，用于对比研究者选择化疗治疗铂耐药复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌。东吴证券指出，JSKN003是公司首款ADC产品，对标DS-8201。
值得注意的是，恒生指数公司公布了其定期的季度指数调整结果。此次适逢恒生综合指数半年度指数审议，这又将成为港股通可投资范围的主要依据。其中，康宁杰瑞制药早剔除出恒生综合指数，华泰证券表示，公司或在3月被调出港股通名单，中金公司研报则未提及公司将被移出港股通。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.